TFXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
TELEFLEX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$129.68−0.75 (-0.58%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- 1.05%
TELEFLEX INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $348.84M | $332.65M | – | $555.90M | $305.06M | $289.73M | $540.79M | $515.89M | $515.63M | $493.98M | $776.63M | $428.21M | 61.2% | +14.4% |
| EMEA | $145.53M | $146.68M | – | $234.25M | $89.85M | $82.64M | $161.04M | $150.22M | $147.06M | $159.66M | $152.37M | $142.72M | 25.5% | +62.0% |
| Asia | $75.96M | $68.93M | – | $122.87M | $47.62M | $41.89M | $93.58M | $98.26M | $87.00M | $84.21M | $88.35M | $93.15M | 13.3% | +59.5% |
| OEM | – | – | – | – | – | – | – | $82.56M | $88.83M | $87.70M | – | $82.31M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | – | – | – | – | – | – | – | $103.68M | $90.67M | $87.99M | – | $126.34M | – |
| EMEA | – | – | – | – | – | – | – | $20.71M | $13.12M | $26.10M | – | $17.88M | – |
| Asia | – | – | – | – | – | – | – | $26.67M | $17.33M | $17.20M | – | $25.98M | – |
| OEM | – | – | – | – | – | – | – | $21.26M | $26.13M | $23.12M | – | $23.49M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vascular | $246.34M | $236.81M | $358.81M | $191.02M | $225.91M | $219.13M | $360.16M | $180.90M | $181.11M | $181.35M | $319.76M | $169.92M | 43.2% | +9.0% |
| Interventional | $211.87M | $204.66M | $73.80M | $266.41M | $113.85M | $100.15M | $160.37M | $149.87M | $141.16M | $134.67M | $31.49M | $134.09M | 37.1% | +86.1% |
| Surgical | $112.12M | $106.79M | $75.45M | $122.88M | $102.76M | $94.98M | $76.30M | $111.75M | $111.30M | $105.52M | $70.54M | $112.81M | 19.7% | +9.1% |
| Other | – | – | – | $79.08M | $59.85M | $53.51M | $58.24M | $54.76M | $41.71M | $52.52M | $68.26M | $76.03M | – | – |
| OEM | – | – | – | $80.41M | $78.68M | $63.88M | $85.43M | $82.56M | $88.83M | $87.70M | $82.57M | $82.31M | – | – |
| Anesthesia | – | – | – | $101.45M | $96.39M | $86.59M | $95.29M | $101.15M | $102.49M | $96.35M | $98.17M | $97.61M | – | – |
| Interventional urology | – | – | – | $71.77M | $76.39M | $70.97M | $84.85M | $83.40M | $83.10M | $79.74M | $92.97M | $73.62M | – | – |
By region
From the segment and revenue-disaggregation notes of Teleflex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.